Oxprenolol (Trasicor)

06/16/1979 - "Oxprenolol appears to be safe and effective in controlling hypertension during pregnancy. "
12/01/1980 - "These factors, in combination with normal peripheral resistance, may contribute to the improvement in foetal outcome described in maternal hypertension of pregnancy treated with oxprenolol."
09/01/1980 - "This feature, in combination with lowered peripheral resistance, may contribute to the improvement in foetal outcome observed in maternal hypertension of pregnancy treated with oxprenolol."
05/01/1989 - "In the International Prospective Primary Prevention Study in Hypertension, 160 mg of slow-release oxprenolol, a beta-blocker with intrinsic sympathomimetic activity, was compared with a diuretic-based regimen not containing beta-blockers. "
06/01/1987 - "In the International Prospective Primary Prevention Study in Hypertension, electrocardiographic changes before and during 3- to 5-year antihypertensive treatment were investigated in a cohort of 5819 men and women aged 40 to 64 years with entry diastolic blood pressures of 100 to 125 mm Hg. They were randomly allocated to treatment regimens that either included or excluded the slow-release beta-blocker oxprenolol. "

01/01/1985 - "Significant reduction of exercise-induced tachycardia persisted for 24 h after administration of oxprenolol Oros. "
06/01/1980 - "oxprenolol was significantly less at 1 and 2 h and significantly greater at 24 h than after conventional oxprenolol, there was little difference between the effects of the two drugs on an exercise tachycardia. "
06/01/1976 - "4 Comparison with placebo showed that the single dose of the conventional oxprenolol produced a significant reduction in exercise induced tachycardia for 8 h whereas the high dose of the slow release preparation produced a similar reduction which lasted for at least 14 hours."
01/01/1985 - "Variations in mean plasma levels and beta-adrenoceptor blockade (measured by inhibition of exercise tachycardia) were considerably reduced on the 10/170 Oros once-daily compared with the Trasicor 80 mg twice-daily regimen. "
06/01/1980 - "At 24 h the percentage reduction in an exercise tachycardia was 8.3 +/- 2.5 after oxprenolol, 10.0 +/- 2.3 after S.R. "

01/01/1987 - "These findings confirm that slow-release oxprenolol is effective in treating chronic stable angina pectoris at the 160-mg dose. "
01/01/1981 - "[Clinical study of delayed-action oxprenolol in the treatment of angina pectoris. "
05/01/1972 - "A total of 254 cases of angina pectoris treated with oxprenolol in hospital practice--a monitored release study."
07/01/1969 - "A single blind trial of Trasicor (Ciba 39,089-Ba) in angina pectoris."
04/19/1969 - "Eighteen patients entered a double-blind trial of the beta-adrenergic blocking drug Trasicor in the treatment of angina pectoris. "

03/01/1988 - "In conclusion, our results confirm the good antihypertensive efficacy of the fixed combination slow-release oxprenolol and chlorthalidone and show that the study medication is able to induce a regression of left ventricular hypertrophy, in hypertensive patients."
01/01/1983 - "This study compared the effects of therapy with oxprenolol (Ox) and with hydrochlorothiazide (Htz) for (1) regression of established left ventricular hypertrophy (LVH) and (2) blood pressure control. "
03/01/1988 - "To evaluate the effects of the chronic administration of the fixed combination slow-release, oxprenolol 160 mg and chlorthalidone 20 mg on left ventricular hypertrophy, ten hypertensive out-patients, with left ventricular hypertrophy documented by left ventricular mass index (LVMI) greater than 130 g/m2, were studied. "
03/01/1988 - "Effects of chronic administration of the fixed combination slow-release oxprenolol-chlorthalidone on left ventricular hypertrophy in hypertensive patients. "
09/01/1986 - "[Reduction of left ventricular hypertrophy and increased tolerance to exertion in hypertensive patients after antihypertensive therapy with slow-release oxprenolol and chlorthalidone]."

06/01/1983 - "Propranolol and oxprenolol raised the ventricular fibrillation threshold by 42 and 56%, respectively. "
08/01/1983 - "A comparison of the two isomers of oxprenolol demonstrated that the (-)-isomer markedly suppressed ischaemic arrhythmias (ventricular ectopic beats, incidence and duration of ventricular tachycardia and duration of ventricular fibrillation) more effectively than the (+)-isomer. "
07/01/1976 - "Procainamide and ajmaline produced a marked protective effect against aconitine-induced ventricular extrasystole, but were not so effective against aconitine-induced ventricular fibrillation, while oxprenolol and, to a lesser degree, propranolol were effective against the latter type of aconitine arrhythmias. "
01/01/1985 - "Thus, inhibition of the fast inward sodium channel with agents such as prenylamine and lignocaine, (when begun before coronary-artery occlusion) offers maximal protection against reperfusion-induced ventricular fibrillation, while beta-blockade with timolol and oxprenolol and slow calcium channel inhibition with nifedipine do not offer any significant protection. "